<DOC>
	<DOCNO>NCT00199433</DOCNO>
	<brief_summary>The primary purpose study evaluate efficacy , safety , tolerability 40 mg per day istradefylline ( KW6002 ) monotherapy patient Parkinson 's disease .</brief_summary>
	<brief_title>A Study Istradefylline ( KW-6002 ) Monotherapy Parkinson 's Disease ( PD ) Patients</brief_title>
	<detailed_description>Parkinson 's disease progressive disease result deterioration motor function result dopamine depletion specific brain structure . Current therapeutic approach include dopamine replacement use dopamine receptor agonist drug . These therapy effective may associate unwanted complication like wear phenomena involuntary abnormal movement ( dyskinesia ) . Istradefylline may provide nondopaminergic approach treatment Parkinson 's disease . This study compare efficacy 40 mg per day istradefylline improve symptom Parkinson 's disease placebo .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>1 . Early PD UKPDS criteria 2 . Mild moderate difficulty daily activity 3 . Females : Either postmenopausal willing use adequate contraception 1 . Unable discontinue current PD medication 2 . Exposure Levodopa 1 month 3 . Symptoms may suggest diagnosis Parkinson 's disease 4 . Medical condition and/or abnormal laboratory finding preclude participation include cancer last 5 year , history drug abuse/dependence , abnormal cognitive status , history seizure , neuroleptic malignant syndrome , psychosis , abnormal liver function test</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Movement Disorder</keyword>
	<keyword>Neurology ,</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>